Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4051 AL 4065

The Methylenetetrahydrofolate Reductase C677T Polymorphism and Risk for Late-Onset Alzheimer's disease: Further Evidence in an Italian Multicenter Study

Stoccoro A, Tannorella P, Salluzzo MG, Ferri R, Romano C, Nacmias B, Siciliano G, Migliore L, Coppedè F.

J Alzheimers Dis. 2017;56(4):1451-1457. doi: 10.3233/JAD-161081.

Therapeutics of Neurotransmitters in Alzheimer's Disease

Kandimalla R, Reddy PH.

J Alzheimers Dis. 2017;57(4):1049-1069. doi: 10.3233/JAD-161118.

Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data

Yoshida K, Roberts R, Suzuki T, Lebowitz B, Reeves S, Howard R, Abe T, Mimura M, Uchida H.

Am J Geriatr Psychiatry. 2017 Jul;25(7):708-716. doi: 10.1016/j.jagp.2017.01.016. Epub 2017 Jan 30.

Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study

Tai SY, Chen CH, Chien CY, Yang YH.

BMC Neurol. 2017 Feb 23;17(1):40. doi: 10.1186/s12883-017-0800-y.

Biophenols pharmacology against the amyloidogenic activity in Alzheimer's disease

Omar SH.

Biomed Pharmacother. 2017 May;89:396-413. doi: 10.1016/j.biopha.2017.02.051. Epub 2017 Feb 27.

Mitochondria in Alzheimer's Disease and Diabetes-Associated Neurodegeneration: License to Heal!

Cardoso SM, Correia SC, Carvalho C, Moreira PI.

Handb Exp Pharmacol. 2017;240:281-308. doi: 10.1007/164_2017_3.

Alzheimer's disease pathology and the unfolded protein response: prospective pathways and therapeutic targets

Koss DJ, Platt B.

Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):161-178. doi: 10.1097/FBP.0000000000000299.

Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease

Calhoun A, Ko J, Grossberg GT.

Expert Opin Emerg Drugs. 2017 Mar;22(1):101-105. doi: 10.1080/14728214.2017.1293651.

Mitochondria-Targeted Molecules as Potential Drugs to Treat Patients With Alzheimer's Disease

Reddy AP, Reddy PH.

Prog Mol Biol Transl Sci. 2017;146:173-201. doi: 10.1016/bs.pmbts.2016.12.010. Epub 2017 Feb 11.

Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs

Caraci F, Sultana J, Drago F, Spina E.

CNS Neurol Disord Drug Targets. 2017;16(4):501-513. doi: 10.2174/1871527316666170303144817.

Amino Acid Catabolism in Alzheimer's Disease Brain: Friend or Foe?

Griffin JW, Bradshaw PC.

Oxid Med Cell Longev. 2017;2017:5472792. doi: 10.1155/2017/5472792. Epub 2017 Feb 5.

Therapeutic potential of nuclear receptor agonists in Alzheimer's disease

Moutinho M, Landreth GE.

J Lipid Res. 2017 Oct;58(10):1937-1949. doi: 10.1194/jlr.R075556. Epub 2017 Mar 6.

Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches

Rüb U, Stratmann K, Heinsen H, Seidel K, Bouzrou M, Korf HW.

J Alzheimers Dis. 2017;57(3):683-696. doi: 10.3233/JAD-161102.

Potential Neuroprotective Effects of Adiponectin in Alzheimer's Disease

Ng RC, Chan KH.

Int J Mol Sci. 2017 Mar 9;18(3):592. doi: 10.3390/ijms18030592.

Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§

Milelli A, De Simone A, Ticchi N, Chen HH, Betari N, Andrisano V, Tumiatti V.

Curr Med Chem. 2017;24(32):3522-3546. doi: 10.2174/0929867324666170309123920.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias